Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1991 May;87(5):1787–1793. doi: 10.1172/JCI115198

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

M Sobel 1, P M McNeill 1, P L Carlson 1, J C Kermode 1, B Adelman 1, R Conroy 1, D Marques 1
PMCID: PMC295293  PMID: 2022745

Abstract

The intravenous administration of heparin to patients before open heart surgery reduced ristocetin cofactor activity by 58% (P less than 0.01, t test), and this impairment of von Willebrand factor-dependent platelet function was closely related to plasma heparin levels (r2 = 0.9), but not to plasma von Willebrand factor (vWF) levels. We hypothesized that heparin may inhibit vWF-dependent platelet hemostatic functions by directly binding vWF in solution and interfering with vWF-GpIb binding. Using the in vitro techniques of ristocetin-induced platelet agglutination, fluorescent flow cytometric measurement of vWF-platelet binding, and conventional radioligand binding assays we observed that heparin inhibited both vWF-dependent platelet function and vWF-platelet binding in a parallel and dose-dependent manner. Heparin also inhibited platelet agglutination induced by bovine vWF and inhibited the binding of human asialo-vWF to platelets in ristocetin-free systems. The inhibitory potency of heparin was not dependent upon its affinity for antithrombin III, but was molecular weight dependent: homogeneous preparations of lower molecular weight were less inhibitory. Heparin impairment of vWF function may explain why some hemorrhagic complications of heparin therapy are not predictable based on techniques for monitoring the conventional anticoagulant effects of heparin.

Full text

PDF
1787

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman B., Carlson P., Powers P. von Willebrand factor is present on the surface of platelets stimulated in plasma by ADP. Blood. 1987 Nov;70(5):1362–1366. [PubMed] [Google Scholar]
  2. Adelman B., Rizk A., Hanners E. Plasminogen interactions with platelets in plasma. Blood. 1988 Nov;72(5):1530–1535. [PubMed] [Google Scholar]
  3. Andersson L. O., Barrowcliffe T. W., Holmer E., Johnson E. A., Sims G. E. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976 Dec;9(6):575–583. doi: 10.1016/0049-3848(76)90105-5. [DOI] [PubMed] [Google Scholar]
  4. Badimon L., Badimon J. J., Rand J., Turitto V. T., Fuster V. Platelet deposition on von Willebrand factor-deficient vessels. Extracorporeal perfusion studies in swine with von Willebrand's disease using native and heparinized blood. J Lab Clin Med. 1987 Nov;110(5):634–647. [PubMed] [Google Scholar]
  5. Berndt M. C., Caen J. P. Platelet glycoproteins. Prog Hemost Thromb. 1984;7:111–150. [PubMed] [Google Scholar]
  6. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem. 1973 Aug;54(2):484–489. doi: 10.1016/0003-2697(73)90377-1. [DOI] [PubMed] [Google Scholar]
  7. De Marco L., Shapiro S. S. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest. 1981 Aug;68(2):321–328. doi: 10.1172/JCI110259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ejim O. S., Powling M. J., Dandona P., Kernoff P. B., Goodall A. H. A flow cytometric analysis of fibronectin binding to platelets from patients with peripheral vascular disease. Thromb Res. 1990 Jun 1;58(5):519–524. doi: 10.1016/0049-3848(91)90257-w. [DOI] [PubMed] [Google Scholar]
  9. Fujimura Y., Titani K., Holland L. Z., Roberts J. R., Kostel P., Ruggeri Z. M., Zimmerman T. S. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem. 1987 Feb 5;262(4):1734–1739. [PubMed] [Google Scholar]
  10. Girma J. P., Meyer D., Verweij C. L., Pannekoek H., Sixma J. J. Structure-function relationship of human von Willebrand factor. Blood. 1987 Sep;70(3):605–611. [PubMed] [Google Scholar]
  11. Girolami A., De Marco L., Virgolini L., Peruffo R., Fabris F. The effect of heparin on platelet aggregation by common inductors and by ristocetin in congenital bleeding disorders due to factor VIII or fibrinogen defects. Blut. 1975 Oct;31(4):219–226. doi: 10.1007/BF01633505. [DOI] [PubMed] [Google Scholar]
  12. Heiden D., Mielke C. H., Jr, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol. 1977 Jul;36(3):427–436. doi: 10.1111/j.1365-2141.1977.tb00666.x. [DOI] [PubMed] [Google Scholar]
  13. Hirsh J., Ofosu F., Buchanan M. Rationale behind the development of low molecular weight heparin derivatives. Semin Thromb Hemost. 1985 Jan;11(1):13–16. doi: 10.1055/s-2007-1004352. [DOI] [PubMed] [Google Scholar]
  14. Holm H. A., Abildgaard U., Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost. 1985 Apr 22;53(2):278–281. [PubMed] [Google Scholar]
  15. Kelton J. G., Bishop J., Carter C. J., Hirsh J. A comparison of the quantitative ristocetin von Willebrand factor assay by using fresh and fixed platelets. Thromb Res. 1980 May 1;18(3-4):477–483. doi: 10.1016/0049-3848(80)90343-6. [DOI] [PubMed] [Google Scholar]
  16. Kermode J. C. Means for the assessment of radioligand quality and its importance in receptor-binding studies. Observations with radiolabelled formylmethionyl-leucyl-phenylalanine. Biochem J. 1988 Jun 1;252(2):521–528. doi: 10.1042/bj2520521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kermode J. C. The curvilinear Scatchard plot. Experimental artifact or receptor heterogeneity? Biochem Pharmacol. 1989 Jul 1;38(13):2053–2060. doi: 10.1016/0006-2952(89)90057-9. [DOI] [PubMed] [Google Scholar]
  18. Kirby E. P., Mills D. C. The interaction of bovine factor VIII with human platelets. J Clin Invest. 1975 Aug;56(2):491–502. doi: 10.1172/JCI108116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. LAURELL C. B. ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS. Anal Biochem. 1965 Feb;10:358–361. doi: 10.1016/0003-2697(65)90278-2. [DOI] [PubMed] [Google Scholar]
  20. Levine M. N., Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost. 1986 Jan;12(1):39–57. doi: 10.1055/s-2007-1003533. [DOI] [PubMed] [Google Scholar]
  21. Lijnen H. R., Hoylaerts M., Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem. 1983 Mar 25;258(6):3803–3808. [PubMed] [Google Scholar]
  22. Markwell M. A. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal Biochem. 1982 Sep 15;125(2):427–432. doi: 10.1016/0003-2697(82)90025-2. [DOI] [PubMed] [Google Scholar]
  23. McPherson J., Brownlea S., Zucker M. B. Effect of monoclonal antibodies against von Willebrand factor and platelet glycoproteins IIb/IIIa on the platelet retention test. Blood. 1987 Aug;70(2):546–550. [PubMed] [Google Scholar]
  24. Menitove J. E., Amrani D. L., Meh D., Frenzke M., Mosesson M. W. Evaluation of factor VIII-rich cryoprecipitate and the plasma fibronectin-rich, heparin-precipitable fraction prepared from single-donor plasma units. Transfusion. 1987 Nov-Dec;27(6):491–495. doi: 10.1046/j.1537-2995.1987.27688071703.x. [DOI] [PubMed] [Google Scholar]
  25. Moake J. L. Insolubilized von Willebrand factor and the initial events in hemostasis. J Lab Clin Med. 1989 Jul;114(1):1–3. [PubMed] [Google Scholar]
  26. Mohri H., Fujimura Y., Shima M., Yoshioka A., Houghten R. A., Ruggeri Z. M., Zimmerman T. S. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem. 1988 Dec 5;263(34):17901–17904. [PubMed] [Google Scholar]
  27. Mohri H., Yoshioka A., Zimmerman T. S., Ruggeri Z. M. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem. 1989 Oct 15;264(29):17361–17367. [PubMed] [Google Scholar]
  28. Moroose R., Hoyer L. W. von Willebrand factor and platelet function. Annu Rev Med. 1986;37:157–163. doi: 10.1146/annurev.me.37.020186.001105. [DOI] [PubMed] [Google Scholar]
  29. Newman J., Johnson A. J., Karpatkin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. Br J Haematol. 1971 Jul;21(1):1–20. doi: 10.1111/j.1365-2141.1971.tb03413.x. [DOI] [PubMed] [Google Scholar]
  30. Pekcelen Y., Inceman S. Letter: Heparin and ristocetin-reduced platelet aggregation. Br Med J. 1975 Oct 11;4(5988):101–102. doi: 10.1136/bmj.4.5988.101-d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Peterson D. M., Stathopoulos N. A., Giorgio T. D., Hellums J. D., Moake J. L. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987 Feb;69(2):625–628. [PubMed] [Google Scholar]
  32. Poncelet P., Carayon P. Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Methods. 1985 Dec 17;85(1):65–74. doi: 10.1016/0022-1759(85)90274-1. [DOI] [PubMed] [Google Scholar]
  33. Ruggeri Z. M., Zimmerman T. S. von Willebrand factor and von Willebrand disease. Blood. 1987 Oct;70(4):895–904. [PubMed] [Google Scholar]
  34. Salzman E. W., Deykin D., Shapiro R. M., Rosenberg R. Management of heparin therapy: Controlled prospective trial. N Engl J Med. 1975 May 15;292(20):1046–1050. doi: 10.1056/NEJM197505152922002. [DOI] [PubMed] [Google Scholar]
  35. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  36. Sobel M., Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res. 1988 Jun 15;50(6):815–826. doi: 10.1016/0049-3848(88)90341-6. [DOI] [PubMed] [Google Scholar]
  37. Suzuki K., Nishioka J., Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta. 1979 Jul 4;585(3):416–426. doi: 10.1016/0304-4165(79)90086-2. [DOI] [PubMed] [Google Scholar]
  38. Switzer M. E., McKee P. A. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure. J Clin Invest. 1976 Apr;57(4):925–937. doi: 10.1172/JCI108369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tangen O., Berman H. J., Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh. 1971 Jun 30;25(2):268–278. [PubMed] [Google Scholar]
  40. Teien A. N., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977 Mar;10(3):399–410. doi: 10.1016/0049-3848(77)90150-5. [DOI] [PubMed] [Google Scholar]
  41. Weinstein M., Ware J. A., Troll J., Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood. 1988 Jun;71(6):1648–1655. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES